Verastem Inc
VSTM
Company Profile
Business description
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Contact
117 Kendrick Street
Suite 500
NeedhamMA02494
USAT: +1 781 292-4200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
78
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.90 | 7.20 | 0.08% |
| CAC 40 | 8,089.23 | 78.50 | -0.96% |
| DAX 40 | 23,981.47 | 223.89 | -0.92% |
| Dow JONES (US) | 48,501.27 | 403.51 | -0.83% |
| FTSE 100 | 10,497.90 | 13.77 | 0.13% |
| HKSE | 25,321.34 | 446.74 | -1.73% |
| NASDAQ | 22,807.48 | 290.79 | 1.29% |
| Nikkei 225 | 55,278.06 | 1,000.99 | -1.78% |
| NZX 50 Index | 13,617.89 | 2.32 | -0.02% |
| S&P 500 | 6,816.63 | 52.87 | -0.77% |
| S&P/ASX 200 | 8,940.30 | 3.30 | 0.04% |
| SSE Composite Index | 4,108.57 | 26.09 | 0.64% |